Evidence map›Paper›PMID 30655811›Full record

ArticleOncology letters2019

Enhanced cytotoxicity of human hepatocellular carcinoma cells following pretreatment with sorafenib combined with trichostatin A.

John Chun-Hao Chen, Hui-Yen Chuang, Yi-Jen Liao, Fei-Ting Hsu, Yen-Chung Chen, Wei-Hsun Wang, Jeng-Jong Hwang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

John Chun-Hao ChenDepartment of Biomedical Imaging and Radiological Sciences, National Yang Ming University, Taipei 112, Taiwan, R.O.C.
Hui-Yen ChuangDepartment of Biomedical Imaging and Radiological Sciences, National Yang Ming University, Taipei 112, Taiwan, R.O.C.
Yi-Jen LiaoSchool of Medical Laboratory and Biotechnology, Taipei Medical University, Taipei 110, Taiwan, R.O.C.
Fei-Ting HsuDepartment of Medical Imaging, Taipei Medical University Hospital, Taipei 110, Taiwan, R.O.C.
Yen-Chung ChenDepartment of Pathology, National Yang Ming University Hospital, Yilan 260, Taiwan, R.O.C.
Wei-Hsun WangDepartment of Orthopedic Surgery, Changhua Christian Hospital, Changhua 500, Taiwan, R.O.C.
Jeng-Jong HwangDepartment of Biomedical Imaging and Radiological Sciences, National Yang Ming University, Taipei 112, Taiwan, R.O.C.
National Yang Ming Chiao Tung University · TWChanghua Christian Hospital · TWTaipei Medical University · TWTaipei Medical University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trichostatin A (TSA), a hydroxamate histone deacetylase inhibitor, is a compound that has been identified to induce anticancer activity. The aim of the present study was to investigate whether sorafenib, in combination with TSA, was able to augment the anticancer effects of TSA, identifying an optimum treatment time plan and the potential underlying molecular mechanisms involved in human hepatocellular carcinoma (HCC)

Indexed as

extracellular-signal-regulated kinasehepatocellular carcinomanuclear factor-κBsorafenibtrichostatin A

Identifiers

PMID30655811
PMCPMC6313190
OpenAlexW2897004900

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.